Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial
Journal
The Lancet Neurology
ISSN
1474-4422
Date Issued
2024
Author(s)
Mukul Sharma
Carlos A Molina
Kazunori Toyoda
Daniel Bereczki
Shrikant I Bangdiwala
Scott E Kasner
Helmi L Lutsep
Georgios Tsivgoulis
George Ntaios
Anna Czlonkowska
Ashfaq Shuaib
Pierre Amarenco
Matthias Endres
Byung-Woo Yoon
David Tanne
Danilo Toni
Laetitia Yperzeele
Paul von Weitzel-Mudersbach
Gisele Sampaio Silva
Alvaro Avezum
Jesse Dawson
Daniel Strbian
Turgut Tatlisumak
Jens Eckstein
Sebastián F Ameriso
Joerg R Weber
Else Charlotte Sandset
Nana Goar Pogosova
Antonio Arauz
David Gailani
Hans-Christoph Diener
Richard A Bernstein
Charlotte Cordonnier
Anja Kahl
Grigor Abelian
Mark Donovan
Chahin Pachai
Danshi Li
Graeme J Hankey
Type
journal-article
Cite this document
Sharma, M., Molina, C. A., Toyoda, K., Bereczki, D., Bangdiwala, S. I., Kasner, S. E., Lutsep, H. L., Tsivgoulis, G., Ntaios, G., Czlonkowska, A., Shuaib, A., Amarenco, P., Endres, M., Yoon, B.-W., Tanne, D., Toni, D., Yperzeele, L., Von Weitzel-Mudersbach, P., Sampaio Silva, G., … Hankey, G. J. (2024). Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (Axiomatic-ssp): A phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. The Lancet Neurology, 23(1), 46-59. https://doi.org/10.1016/S1474-4422(23)00403-9